Testing for early detection & monitoring of Cancer
Survivorship starts the moment you find out you are at risk.
Unlock the power of EARLY DETECTION
The power of liquid biopsy lies in its ability to detect cancer at an early stage, when it is most treatable.
Liquid biopsy has emerged as a promising tool for detecting cancer-related abnormalities in a minimally invasive manner. It involves the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and other biomarkers present in the blood. Integrating liquid biopsy-based approaches into clinical practice has the potential to improve patient outcomes by enabling eraly detection, timely treatment adjustments and minimizing invasive procedures.
A NON-INVASIVE way to Detect Cancer
DATAR TRUCHECK INTELLI™
1
Early Detection allows a person to take control of their health and seek appropriate medical care if any abnormalities are found.
Studies show that early detection improves outcomes for both eradication and effective control of cancer. This is because Early-stage cancers are generally smaller and have not spread to nearby tissues or other parts of the body.
This makes them more amenable to surgical removal, and potentially less invasive treatment options.
EARLY DETECTION
& TREATMENT MONITORING
Identify cancer mutations, track treatment progress, and avoid invasive procedures.
Liquid biopsy enables the detection and monitoring of cancer using a simple blood sample.
Unlike traditional biopsies which require the removal of tissue from a tumor, liquid biopsy is a minimally invasive procedure that can provide valuable information about a patient's cancer without the need for surgery or an invasive procedure.
.
Liquid biopsy can also be used to identify cancer mutations, and monitor cancer during treatment, providing real-time information about how a patient is responding to therapy.
In some cases both tumor tissue biopsy and liquid biopsy may be used together to provide a more complete picture of your cancer. For example, a tissue biopsy may be used to determine the type and characteristics of the cancer, while a liquid biopsy may be used to monitor the response to treatment or detect cancer recurrence.
As this diagnostic technology continues to advance, liquid biopsy has the potential to transform the way we approach cancer care , leading to earlier diagnosis, better outcomes and improved quality of life for cancer patients. This makes liquid biopsy a valuable tool in the diagnosis and treatment of cancer
.
DATAR eXACTA 360™
Encyclopedic Interrogation of Cancer
Identify Tumor Dynamics
2
Working to Revolutionize Cancer Care Through Innovative Solutions
Every cancer and every patient is different; consequently, treatments that are not customized for each patient have lesser chances of succeed. Additionally, cancer cells are known to evade and survive treatments leading to gradual ineffectiveness and recurrence.
Our solutions offer deep genomic and cellular analysis of a patient’s cancer that can help identify personalized treatment strategies.
DATAR chemo-scale™
ELIMINATE GUESSWORK
Chemo - resistance Profiling of Circulating Tumor Associated Cells
3
Chemo-scale™ evaluates in vitro chemo-resistance in CTCs, which are known to be present (and detected ubiquitously) in almost all solid organ tumors, irrespective of age, gender, primary organ, subtype, grade, stage or treatment status.
Since CTACs include CTCs as well as TACs which play an important role in sustaining a malignancy, determination of chemo-resistance in CTACs has high correlation with tumor tissues. Datar's prior acclaimed clinical studies have shown that CTAC based determination of in vitro chemo-resistance has high concordance with tumor tissue-based determinations as well as with clinical outcomes.
PERSONALIZE, PLAN AND TRACK TREATMENT
DATAR CANCER GENETICS our partner in cancer detection and management.
Cancer cells shed DNA into the bloodstream as they grow and multiply. By looking for these tiny pieces of circulating tumor DNA (ctDNA) circulating in bloodstream, then analyzing them, it is possible to detect the presence of cancer, identify its genetic makeup, help to choose a good treatment protocol, then monitor how one is responding to treatment.
Liquid biopsies can provide real-time monitoring of tumor dynamics, identification of actionable genetic alterations and early detection of treatment resistance. Providing an opportunity for a more individualized approach to treat and monitor cancer.
A Liquid Biopsy can help you and your Doctors to tailor treatment plans and monitor your response.
Oncotarget: RESILIENT Trial Results
Oncotarget published this top-performing paper on September 24, 2019, entitled, “Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial,” by researchers from HCG Manavata Cancer Centre, India; Datar Cancer Genetics Limited, India; St. Luke’s Cancer Center, Royal Surrey County Hospital, UK; Worcester Polytechnic Institute, USA.
© calmovercancer.COM | ALL RIGHTS RESERVED | TERMS & CONDITIONS | MEDICAL DISCLAIMER